NCT05675202View on ClinicalTrials.gov

Material Balance Study of TQ-B3525

PHASE1UnknownINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 31, 2023

Primary Completion Date

August 31, 2023

Study Completion Date

December 31, 2023

Conditions
Chronic Kidney DiseasesMagnetic Resonance Imaging
Interventions
DRUG

TQ-B3525

TQ-B3525 is a new PI3K α/δ Kinase inhibitor

Trial Locations (1)

215006

The First Affiliated Hospital of Soochow University, Suzhou

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY